Kp7-6

An exocyclic cysteine-knot peptide that specifically antagonizes Fas/FasL-mediated cellular apoptotic signals (58% reduction of FasL-induced apoptosis in Jurkat cells at 1 mg/ml). Binds to FasL (Cat. Nos. PF033 and PF092) and Fas (CD95/APO-1) with comparable affinity (K_d = 11.2 & 13.2 µM, respectively), resulting in disabled receptor ensembles and altered signaling. Shown to prevent Con A (Cat. No. 234567)-induced liver injury in a murine hepatitis model in vivo. Does not bind to TNF-α or TNFR.

An exocyclic cystine-knot peptide that specifically antagonizes Fas/FasL-mediated cellular apoptotic signals (58% reduction of FasL-induced apoptosis in Jurkat cells at 1 mg/ml). Binds to FasL (Cat. Nos. PF033 and PF092) and Fas (CD95/APO-1) with comparable affinity (K_d = 11.2 & 13.2 µM, respectively), resulting in disabled receptor ensembles and altered signaling pathways. Shown to prevent Con A (Cat. No. 234567)-induced liver injury in a murine hepatitis model in vivo. Does not bind to TNF-α or TNFR.

Cell permeable: no

Kd = 11.2 & 13.2 µM for FasL and Fas (CD95/APO-1), respectively

Primary Target
Fas/FasL-mediated cellular apoptotic signals

Product does not compete with ATP.

Reversible: no

Packaged under inert gas

Toxicity: Standard Handling (A)

H₂N-Tyr-Cys*-Asp-Glu-His-Phe-Cys*-Tyr-CO₂H, Cyclic [disulfide bond between Cys-Cys]

Supplied as a trifluoroacetate salt.

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Carmona, E.M., et al. 2006. J. Immunol.177, 459.
Hasegawa, A., et al. 2004. Proc. Natl. Acad. Sci. USA101, 6599.

Sold under license of U.S. Patent 7,288,519.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany